Nicotine Addiction - Pipeline Review, H1 2016

Published: Mar, 2016 | Pages: 60 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Nicotine Addiction - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Nicotine Addiction - Pipeline Review, H1 2016', provides an overview of the Nicotine Addiction pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Nicotine Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nicotine Addiction and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Nicotine Addiction
- The report reviews pipeline therapeutics for Nicotine Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Nicotine Addiction therapeutics and enlists all their major and minor projects
- The report assesses Nicotine Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Nicotine Addiction


Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Nicotine Addiction
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nicotine Addiction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Nicotine Addiction Overview 7
Therapeutics Development 8
Pipeline Products for Nicotine Addiction - Overview 8
Pipeline Products for Nicotine Addiction - Comparative Analysis 9
Nicotine Addiction - Therapeutics under Development by Companies 10
Nicotine Addiction - Therapeutics under Investigation by Universities/Institutes 11
Nicotine Addiction - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Nicotine Addiction - Products under Development by Companies 14
Nicotine Addiction - Products under Investigation by Universities/Institutes 15
Nicotine Addiction - Companies Involved in Therapeutics Development 16
Addex Therapeutics Ltd 16
Astraea Therapeutics, LLC 17
Cerecor Inc. 18
Embera NeuroTherapeutics, Inc. 19
Hager Biosciences, LLC 20
Heptares Therapeutics Limited 21
Omeros Corporation 22
RTI International 23
Nicotine Addiction - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Combination Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 31
Drug Profiles 33
(metyrapone + oxazepam) - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ADX-71441 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
AT-1001 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
CERC-501 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Drugs to Inhibit FAAH for CNS Disorders - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
EORA-101 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
OMS-405 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
OMS-527 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Small Molecule to Antagonize Alpha-4 Beta-2 Nicotinic Acetylcholine Receptor for CNS Disorders - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Small Molecules to Antagonize CRF-R1 and OREXIN-1 for Nicotine Addiction - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Vaccine for Nicotine Addiction - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Vaccine for Nicotine Addiction - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Nicotine Addiction - Recent Pipeline Updates 49
Nicotine Addiction - Dormant Projects 54
Nicotine Addiction - Discontinued Products 55
Nicotine Addiction - Product Development Milestones 56
Featured News & Press Releases 56
Dec 11, 2015: Publication Reports Human Brain Penetration and Target Engagement of Cerecor's Oral Kappa Opioid Receptor Antagonist, CERC-501 56
Jul 10, 2014: Addex ADX71441 Positive Results in Preclinical Model of Nicotine Addiction 56
Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction 57
May 05, 2011: Omeros Announces Expansion Of Potential Indications For PDE7 Inhibitors 57
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 59
Disclaimer 60

List of Tables
Number of Products under Development for Nicotine Addiction, H1 2016 8
Number of Products under Development for Nicotine Addiction - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Development, H1 2016 13
Products under Development by Companies, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Nicotine Addiction - Pipeline by Addex Therapeutics Ltd, H1 2016 16
Nicotine Addiction - Pipeline by Astraea Therapeutics, LLC, H1 2016 17
Nicotine Addiction - Pipeline by Cerecor Inc., H1 2016 18
Nicotine Addiction - Pipeline by Embera NeuroTherapeutics, Inc., H1 2016 19
Nicotine Addiction - Pipeline by Hager Biosciences, LLC, H1 2016 20
Nicotine Addiction - Pipeline by Heptares Therapeutics Limited, H1 2016 21
Nicotine Addiction - Pipeline by Omeros Corporation, H1 2016 22
Nicotine Addiction - Pipeline by RTI International, H1 2016 23
Assessment by Monotherapy Products, H1 2016 24
Assessment by Combination Products, H1 2016 25
Number of Products by Stage and Target, H1 2016 27
Number of Products by Stage and Mechanism of Action, H1 2016 29
Number of Products by Stage and Route of Administration, H1 2016 30
Number of Products by Stage and Molecule Type, H1 2016 32
Nicotine Addiction Therapeutics - Recent Pipeline Updates, H1 2016 49
Nicotine Addiction - Dormant Projects, H1 2016 54
Nicotine Addiction - Discontinued Products, H1 2016 55